Please see the following article from Infectious Disease Special Edition (IDSE) propagating the same old BS…

Note: The email address for Myles Starr was returned as “Undeliverable” but the email for Meaghan Lee Callaghan, Managing Editor of this publication is correct. 

---------- Original Message ----------
From: CARL TUTTLE <runagain@comcast.net>
To: "mstarr@mcmahonmed.com" <mstarr@mcmahonmed.com>
Cc: "mcallaghan@mcmahonmed.com" <mcallaghan@mcmahonmed.com>
Date: 12/25/2025 10:48 AM EST
Subject: HHS Announces New Efforts to Tackle Lyme Disease (IDSE)
 
 
Infectious Disease Special Edition (IDSE) 
DECEMBER 19, 2025
 
HHS Announces New Efforts to Tackle Lyme Disease (IDSE)
https://www.idse.net/Bacterial-Infections/Article/12-25/lyme-disease-diagnosis-insurance-coverage-HHS-funding/79249
 
By Myles Starr
 
Quote from Dr. Paul Auwaerter:
 
“There is a history of people suffering from problems such as fatigue, pain, sleep difficulties, and brain fog that have been attributed to Lyme disease, but it’s unclear in many of those patients whether Lyme disease is the cause of those symptoms,” he said.
 
 
 
To: Myles Starr,
 
Did Dr. Auwaerter mention that he was a coauthor of the Johns Hopkins study that identified the reason why antibiotics weren’t working for Lyme disease?
 
Here is a timeline of events:
 
2015
 
Standard antibiotic treatment for Lyme disease does not kill persistent Borrelia bacteria. 
http://droopyyoupi.blogspot.com/2015/08/standart-antibiotic-treatment-for-lyme.html
 
Excerpt:
 
-What has tuberculosis and Borrelia burgdorferi in common? In the late stage of the disease occurs persistent (tolerant) bacteria, which essentially means that the bacteria lasts and lasts and lasts. They protect themselves against antibiotics and are difficult to treat.
 
- Both Borrelia burgdorferi and tuberculosis is relatively easy to cure in the early stages, even with the use of one antibiotic. In the late stage it is impossible to cure the disease with the same type of treatment in the acute phase, said Dr. Ying Zhang when he visited the year NorVect conference.
 
-Dr. Ying Zhang is a professor at the Department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health
 
-Two days after NorVect conference, published Dr. Ying Zhang's latest research Identification of new compounds with high activity against stationary phase Borrelia burgdorferi from the NCI compound collection.
 
 
2016
 
A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug Library
Jie Feng 1, Wanliang Shi 1, Shuo Zhang 1, David Sullivan 1, Paul G Auwaerter 2, Ying Zhang 1
https://pubmed.ncbi.nlm.nih.gov/27242757/
 
Abstract
 
Under experimental stress conditions such as starvation or antibiotic exposure, Borrelia burgdorferi can develop round body forms, which are a type of persister bacteria that appear resistant in vitro to customary first-line antibiotics for Lyme disease. To identify more effective drugs with activity against the round body form of B. burgdorferi, we established a round body persister model induced by exposure to amoxicillin (50 μg/ml) and then screened the Food and Drug Administration drug library consisting of 1581 drug compounds and also 22 drug combinations using the SYBR Green I/propidium iodide viability assay. We identified 23 drug candidates that have higher activity against the round bodies of B. burgdorferi than either amoxicillin or doxycycline. 
 
 
2022
  
Nitroxoline Drug Combinations Are More Active Than Lyme Antibiotic Combination and Can Eradicate Stationary-Phase Borrelia burgdorferi
Alvarez-Manzo, Hector S.1; Zhang, Yumin1; Zhang, Ying2,✉
https://journals.lww.com/imd/fulltext/2022/09000/nitroxoline_drug_combinations_are_more_active_than.7.aspx
 
Abstract
 
Lyme disease (LD), caused by Borrelia burgdorferi, is the most common vector-borne disease in the United States and Europe. Despite the standard 2–4 weeks' antibiotic treatment, approximately 10%–20% of patients will develop posttreatment LD syndrome, a condition that is poorly understood. One of the probable causes is thought to be the presence of B. burgdorferi persister forms that are not effectively killed by the current LD antibiotics. In this study, we evaluated nitroxoline, an antibiotic used to treat urinary tract infections, for its activity against a stationary-phase culture enriched with persister forms of B. burgdorferi. Nitroxoline was found to be more active than doxycycline and equally active as cefuroxime (standard LD antibiotics) against B. burgdorferi. Importantly, the nitroxoline two-drug combinations nitroxoline + cefuroxime and nitroxoline + clarithromycin, as well as the nitroxoline three-drug combination nitroxoline + cefuroxime + clarithromycin, were as effective as the persister drug daptomycin-based positive control three-drug combination cefuroxime + doxycycline + daptomycin, completely eradicating stationary-phase B. burgdorferi in the drug-exposure experiments and preventing regrowth in the subculture study. Future studies should evaluate these promising drug combinations in a persistent LD mouse model.
 
 
Myles Starr….
 
It appears that Auwaerter did mention the fact that he is involved with the current Lyme vaccine:
 
“Dr. Auwaerter reported that he is an investigator for the VALOR trial, which is a phase 3 Lyme disease vaccine trial.”
 
Suggestion:
 
Ask Auwaerter if a chronic relapsing seronegative disease fits the vaccine model.
 
Google’s Gemini AI says the following: “A chronic, relapsing, seronegative disease does not fit the traditional vaccine model, which is primarily designed to prevent initial infections. The characteristics you describe present significant scientific and commercial challenges for vaccine developers.”
 
You can read more about this subject in a personal email I recently sent to Dr. Robert Redfield past director of the CDC which offers an explanation for the chronic Lyme denialism.
 
Dr. Redfield Breaks His Silence — Long COVID, Cancer & Vaccines [And Chronic Lyme]
https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/34045161
 
 
Respectfully Submitted,
 
 
Carl Tuttle
Independent Researcher
Hudson, NH
 
Cc: Meaghan Lee Callaghan, Managing Editor